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significant advances in the understanding of the pro-2Department of Molecular Genetics
cesses that regulate bone mass (Marks, 1989). From3Department of Protein Chemistry
these studies we have learned the following: (i) genetic4Department of Computational Biology
defects in osteoclast development, maturation, and/or5Department of Mammalian Cell Molecular Biology
activation lead to decreased bone resorption and uni-6Department of Immunology
formly result in severe osteopetrosis (Marks, 1989); (ii)7Department of Pathology
the stromal microenvironment plays an essential role8Department of Bacterial Expression
in osteoclast differentiation (Udagawa et al., 1989); (iii)9Department of Protein Structure
signal transduction from the cell membrane through Src10Department of Process Science
tyrosine kinase is necessary for osteoclast-mediated
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bone resorption (Soriano et al., 1991); and (iv) changes
1840 DeHavilland Drive in gene expression patterns regulated by the nuclear
Thousand Oaks, California 91320 factor Fos play an important role in osteoclast develop-
ment (Wang et al., 1992; Grigoriades et al., 1994). Addi-
tionally, osteoclast maturation and activation are regu-
Summary lated by osteoblast-derived factors during remodeling
(Rodan and Martin, 1981). The disregulation of osteo-
A novel secreted glycoprotein that regulates bone re- blast and osteoclast functions in these systems impli-
sorption has been identified. The protein, termed Os- cates genes that act as key determinants in the regula-
teoprotegerin (OPG), is a novel member of the TNF tion of bone mass. However, relatively little is known
about the soluble factors that act physiologically to reg-receptor superfamily. In vivo, hepatic expression of
ulate osteoclast development.OPG in transgenic mice results in a profound yet non-
This report describes the isolation of a determinantlethal osteopetrosis, coincident with a decrease in
in the regulation of bone mass, a novel secreted memberlater stages of osteoclast differentiation. These same
of the tumor necrosis factor receptor (TNFR) superfam-effects are observed upon administration of recom-
ily. The TNFR superfamily consists mostly of transmem-binant OPG into normal mice. In vitro, osteoclast dif-
brane proteins that elicit signal transduction in a varietyferentiation from precursor cells is blocked in a
of cells. This novel member lacks any apparent cell-dose-dependent manner by recombinant OPG. Fur-
association signals, however, indicating it likely acts inthermore, OPG blocks ovariectomy-associated bone
the extracellular milieu. Transgenic mice expressing thisloss in rats. These data show that OPG can act as a
secreted protein exhibit a generalized increase in bonesoluble factor in the regulation of bone mass and imply
density (osteopetrosis) associated with a decrease ina utility for OPG in the treatment of osteoporosis asso-
osteoclasts. We named this protein Osteoprotegerinciated with increased osteoclast activity.
(OPG), i.e., to protect bone. Administration of recombi-
nant OPG produces similar effects in normal mice and
Introduction protects against ovariectomy-associated bone loss in
rats. In vitro, OPG blocks osteoclastogenesis in a dose-
Bone is a complex tissue composed of cells, collage- dependent manner. OPG appears to block the differenti-
nous matrix, and inorganic elements. It provides many ation of osteoclasts, the principal if not sole bone-
essential functions, including mechanical support, pro- resorbing cell type, suggesting that it can act as a
tection of vital organs, a microenvironment for hemato- humoral regulator of bone resorption.
poiesis, and a depot for calcium and other minerals. The
growth, development, and maintenance of bone is a Results
highly regulated process (Nijweide et al., 1986). The level
of bone mass reflects the balance of bone formation Identification and Isolation of a Novel
and resorption, which at the cellular level involves the Secreted TNFR-Related Protein
coordinate regulation of bone-forming cells (osteo- OPG was first identified by sequence homology as a
blasts) and bone-resorbing cells (osteoclasts). Osteo- possible novel member of the TNFR superfamily during
blasts arise from mesenchymal stem cells and produce a fetal rat intestine cDNA-sequencing project. A full-
length version of this clone was isolated and sequencedbone matrix during development, after bone injury, and
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Figure 1. Osteoprotegerin Protein Structure
and Secretion in Mammalian Cells
(A) Structure of the 2.4 kb rat intestinal pB1.1
clone indicating the position of the 401 aa
open reading frame (bar). The closed box rep-
resents the 21-residue signal peptide, and
shaded circles indicate the position of the 4
TNFR-like cysteine-rich domains.
(B) Alignment of human, mouse, and rat
amino acid sequences. The location of the
signal peptide cleavage site is indicated by
a descending arrowhead. The four N-terminal
TNFR-like cysteine-rich domains located be-
tween residues 22 and 194 are labeled I±IV.
The predicted disulfide linkages (SS) for do-
mains I±IV are indicated by bold lines. Either
tyrosine 28 or 31 and histidine 75 (underlined)
are predicted to form an ionic interaction. The
cysteine residues located in the C-terminal
half of OPG are boxed.
(C) Pulse-chase analysis of recombinant mu-
rine OPG produced in CHO cells. Cells were
pulse-labeled for 30 min, then chased for the
indicated time. Extracts of cells (left panel)
and conditioned media (right panel) were im-
munoprecipitated, then analyzed by SDS±
PAGE under nonreducing conditions. The rel-
ative mobility of the 55 kDa monomer and 110
kDa dimer are indicated.
(Figure 1A). This novel cDNA encodes a 401 amino acid proteins nor contained any recognizable protein motifs.
These data suggest that the rat opg cDNA encodes a(aa) polypeptide that has features of a secreted glyco-
protein, such as a hydrophobic leader peptide, and 4 novel secreted member of the TNFR family. Mouse and
human opg cDNA clones isolated from normal kidneypotential sites of N-linked glycosylation (Figure 1B). Al-
though there were no existing matches in the database cDNA libraries also encode 401 aa proteins. The mouse
and human proteins are z85% and 94% identical to theto the 401 aa reading frame, the predicted N-terminal
half of the protein has a strong similarity to all members predicted rat protein, respectively, indicating that the
opg gene has been highly conserved throughout evolu-of the TNFR superfamily, most notably TNFR-2 and
CD40. Unlike other known TNFR-like molecules, how- tion (Figure 1B).
Pulse-chase labeling and immunoprecipitation of ex-ever, this protein contains no hydrophobic transmem-
brane-spanning sequence. The C-terminal half of OPG tracts obtained from OPG-transfected Chinese hamster
ovary (CHO) cells show that OPG is a naturally secreted(aa 195±401) showed no homologies to any other known
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Figure 2. opg mRNA Expression in Tissues
and during Mouse Embryogenesis
(A) Northern blot of poly(A)1 mouse tissue or
whole embryo RNA probed with a mouse opg
cDNA probe (upper panel) or with a mouse
gapdh cDNA probe (lower panel).
(B) Northern blot of poly(A)1 human tissue
RNA probed with a human opg cDNA probe
(upper panel) or a mouse gapdh cDNA probe
(lower panel). Both mouse and human OPG
transcripts migrate as an approximately 3.0
kb band.
(C) In situ hybridization analysis of mouse opg
mRNA expression in an E15 mouse embryo.
Shown here is a saggital section of an E15
BDF1 mouse embryo that was hybridized
overnight with [ 35S]UTP antisense riboprobe
for the detection of murine opg mRNA. Sense
probe was used as a control and showed no
signal (data not shown). Note the high expres-
sion of opg mRNA in cartilage rudiments of
developing bones and in several major arter-
ies, the gastrointestinal tract, and skin.
glycoprotein (Figure 1C). Initially, OPG is synthesized as intestines, skin, and calvaria (data not shown). In human
tissues, a transcript of similar size is detected at highestan approximately 55 kDa monomer within the cell, is
next converted to a disulfide-linked dimer of approxi- levels in the lung, heart, kidney, and placenta (Figure
2B), although there are detectable levels in various he-mately 110 kDa, and is then secreted into the media
(Figure 1C). While smaller amounts of monomeric OPG matopoietic and immune organs (data not shown). Dur-
ing mouse embryonic development, opg transcripts arealso are secreted, the predominant extracellular form of
OPG is a disulfide-linked dimer. The monomeric and detected at high levels on day 7, whereas expression
decreases at day 11 and then increases from day 15 todimeric forms of OPG have been individually purified,
and their N-terminal sequence has been determined day 17 (Figure 2A). Since opg mRNA is expressed at
relatively high levels in bothmouse and human placenta,(P. D., unpublished data). Both forms of OPG are cleaved
during processing just before the glutamic acid residue opg transcripts detected at day 7 may be due to the
association of the placenta with the embryo at this de-at position 22 (Figure 1B), giving rise to a 380-residue
mature protein. Under reducing conditions, OPG mi- velopmental stage. Interestingly, there is a strikingly dif-
ferent pattern of OPG expression when comparinggrates as an approximately 55 kDa protein, larger than
the 40 kDa predicted size of the mature polypeptide mouse and human tissues, most noticeably between
brain, liver, and kidney. The reason for this is not clear,chain (data not shown). Upon treatment of purified OPG
with N-glycanase, it migrates on reducing gels with an but it may reflect authentic differences in opg gene ex-
pression patterns between these two species. Alterna-Mr of about 40 (M. K. and P. D., unpublished data),
indicating that OPG is a glycoprotein. Together with the tively, the levels of opg mRNA may physiologically vary,
an aspect of this novel molecule that will need furtherstructural data described above, this suggests that OPG
functions outside the cell as a secreted molecule capa- study. Since OPG is a secreted protein, however, the
site of its expression does not necessarily predict theble of forming covalently bonded homodimers.
site(s) at which it exerts its biological function.
Detection of opg mRNA transcripts by in situ hybrid-Patterns of OPG Expression in Mouse Tissues
opg transcripts of about 3.0 kb were detected by North- ization in a day 15 mouse embryo is shown in Figure
2C. There is prominent expression of opg transcriptsern blot hybridization in a number of murine tissues,
including liver, lung, heart, and kidney (Figure 2A). opg within the cartilagenous primordia of developing bone,
most noticeably in themaxilla, mandible, the hyoid bone,mRNA is also expressed at high levels in the stomach,
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Figure 3. Increased Bone Density in opg Transgenic Mice
Two 10-week-old founder mice expressing relatively high (animal 17, bottom row) and low (animal 11, middle row) levels of opg transgene
mRNA, and control littermate mouse (animal 18, top row) were subjected to X-ray (left column) or histologic (middle and right columns) analysis
of their long bones, pelvis, and vertebrae. Increased bone density is seen in radiographs of transgenics 11 and 17, as are visible increases
in bone by histological analysis. The lower power magnification (right column; bar 5 1 mm) shows the distal femur and growth plate, and the
higher power magnification (middle column; bar 5 100 mm), shows the femoral midshaft. In these sections, bone stains deep blue or red,
cartilage stains light blue, and marrow stains dark purple. Note the marbling effect reflecting the retention of cartilage remnants within
trabeculae and the poorly defined cortex in the opg transgenics, particularly in animal 17 (lower middle and lower right panels, respectively).
Increases in bone density are visible at birth in the high expressors and are detected with 100% penetrance in transgenic mice with elevated
circulating levels of OPG.
the basiphenoid and basioccipital bones, the ribs, and product was successfully delivered to the systemic cir-
culation (W. S. S. and W. J. B., unpublished data).the vertebrae. High expression was also detected in the
The OPG-expressing animals and their normal lit-brachiocephalic artery and ductus arteriosus, the left
termates had no differences in external appearance,main bronchus, the abdominal aorta, and the midgut.
behavior, or bodyweight. Radiographs of intact animals
showed a generalized increase in radiodensity of the
OPG Increases Bone Density In Vivo long bones, vertebrae, and pelvis characteristic of os-
To gain insights into the potential biological function for teopetrosis (Figure 3, left column). Despite this increase
OPG, transgenic mice were generated that express the in radiodensity, there were no abnormalities in tooth
rat opg cDNA under the control of the human apolipo- eruption, which has been observed in other osteope-
protein E gene promoterand its associated liver-specific trotic mice (Yoshida et al., 1990; Soriano et al., 1991;
enhancer (Simonet et al., 1993). This vector has been Wang et al., 1992). Additionally, the relative size and
previously used to generate mice containing high levels shape of the bones in the expressors were not different
of secreted protein in their circulation (Simonet et al., from those of control mice. Upon gross dissection,
1994). Since OPG is a secreted receptor,any observable splenomegaly was the only abnormality found in the
phenotype in mice overexpressing this protein should transgene expressors. Analysis of organ weights indi-
be the result of interactions with its cognate ligand, cated that only the spleens were increased (by z38%) in
whether it is a soluble or a cell-surface protein. Five the transgenic mice relative to controls. High expressors
founder mice harboring the rat opg transgene were iden- exhibited clear signs of osteopetrosis by radiography
tified by Southern blot analysis of ear DNA samples and immediately following birth, with increasing severity
were analyzed at 8±10 weeks of age. Four of the five throughout adolescence and adult life.
founders were found to express varying levels of Histological analysis of bone sections from OPG ex-
transgene mRNA in their livers (data not shown). The pressors (Figure 3, founder animals 11 and 17) show
rat OPG monomer and dimer were easily detectable in severe osteopetrosis with the presence of trabeculae
liver extracts and serum of high expressing transgenic formed of bone-encased cartilage in the mid-diaphysis of
the femur (Figure 3, middle column), a location normallymice but not control mice, indicating the transgene
A Novel Secreted Osteoclastogenesis Inhibitor
313
Figure 4. opg Transgenics Do Not Have a
Defect in Monocyte±Macrophage Develop-
ment but Appear to Have a Defect in Osteo-
clast Formation
Osteoclasts (arrows) in the distal femoral me-
taphysis were identified by TRAP cytochem-
istry. Many large multinucleated osteoclasts
were present on the surface of metaphyseal
trabecular bone in normal mice (A), while in
the opg transgenic mice (B) only a few small
TRAP-positive cells (possibly inactive osteo-
clasts) were seen in the same region. A carti-
lage remnant is marked ªc,º and its edge
marked by arrowheads (bar 5 10 mm). To
confirm the presence of tissue macrophages,
which share a common precursor with
osteoclasts, immunohistochemistry was per-
formed using anti-F480 antibodies, which
recognize a cell-surface antigen on murine
macrophages. The bottom panels are photo-
micrographs of spleens from either normal
(C) or opg transgenic (D). Numerous F480-
positive cells (brown staining) are detected
in both spleens (bar 5 100 mm). This is in
marked contrast to what is observed in the osteopetrotic Op mice, which exhibit a defect in monocyte±macrophage development and a
corresponding decrease in F480-positive cells in their spleens (Yoshida et al., 1990), suggesting that OPG is functioning to block osteoclast
development at a more terminal step than the divergence of macrophage and osteoclast precursors.
filled by hematopoietic elements. The severity of the os- the relative level of hepatic opg transgene mRNA. Circu-
lating levels of OPG in these founder mice were notteopetrosis correlated with the level of opg mRNA. In the
highest expressors, a clearly defined cortex was not iden- determined. However, F1 transgenic progeny with ra-
diographic and histological bone changes similar totifiable in sections of the femur (Figure 3, right column).
Sections of vertebrae also show osteopetrotic changes, founder mice 17 and 11 (Figure 3) had circulating OPG
levels of 358 6 79 and 14.2 6 3.6 ng/ml (mean 6 SD),implying that the OPG-induced skeletal changes were
systemic. Von Kossa staining of nondecalcified bone respectively. Penetrance of the osteopetrotic phenotype
was found to be 100% in mice with serum OPG levelssections showed that the increased bone/cartilage ma-
trix was mineralized (data not shown). Coincident with greater than 10 ng/ml and varied in severity proportional
to the level of systemic OPG. In contrast, OPG levels inthe loss of the marrow cavities, the spleens from the
OPG expressors had an increased amount of red pulp, the normal littermates were less than 2 ng/ml. (L. B.,
unpublished data).likely resulting from compensatory hematopoiesis ow-
ing to occlusion of marrow cavities with bone and carti- The residual marrow present as islands within the os-
teosclerotic bone of high expressors showed predom-lage. In addition to this, the highest OPG expressors
had foci of extramedullary hematopoiesis within the liver inantly myeloid elements. Megakaryocytes also were
present at normal levels. Immunohistochemical staining(data not shown).
There were no other apparent gross pathologies in of tissues for F480, a cell-surface antigen expressed
by osteoclast precursors of the monocyte±macrophagethese mice, nor histologic abnormalities in the thymus,
lymph nodes, gastrointestinal tract, pancreato-hepato- lineage (Austyn and Gordon, 1981), showed the pres-
ence of positive cells in themarrow spaces and flattenedbiliary tract, respiratory tract, reproductive system, gen-
ito-urinary system, skin, nervous system, heart and directly adjacent to trabecular bone surfaces (data not
shown). All hematopoietic elements and F480-positiveaorta, breast, skeletal muscle, or fat.These observations
underscore theapparent skeletalselectivity of transgen- cells were present in red pulp of both control and OPG
mice (Figures 4C and 4D). In contrast, F480-positiveically expressed opg activity.
The observed increase in bone density seen in opg cells are virtually absent in Op mutant mice, which carry
a defective csf-1 gene (Yoshida et al., 1990). The pres-transgenic mice could be due either to increased osteo-
blast synthesis of bone matrix or, conversely, to de- ence of F480-positive cells in opg transgenic mice rules
out a generalized decrease in osteoclast precursors ascreases in osteoclast-mediated bone resorption. The
analysis of bone sections suggests that the latter pro- the basis for the effects of OPG and suggests that OPG
might regulate the terminal stages of osteoclast differen-cess was affected. Based on H and E and tartrate-resis-
tant acid phosphatase (TRAP) stains, the predominant tiation.
difference in the expressors was the profound decrease
in trabecular osteoclasts, both in the vertebrae and fe-
murs (Figures 4A and 4B). This was particularly evident Recombinant OPG Blocks Osteoclastogenesis
In Vitroin the most severely affected animals. Similar to the
severity of the osteopetrosis observed histologically, To determine whether or not OPGacts to regulate osteo-
clast differentiation, its effects were tested in an in vitrothe magnitude of osteoclast deficiency correlated with
Cell
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Figure 5. OPG Inhibits Osteoclastogenesis
In Vitro
(A and B) Increasing concentrations of murine
OPG [22±401]-Fc protein cause a dose-
dependent decrease in the appearance of
TRAP-positive osteoclasts (A) and TRAP ac-
tivity (B) in osteoclast-forming cultures using
splenocytes from either transgenic mice or
their normal littermates (for assay details, see
Experimental Procedures). Large multinucle-
ated cells stained purple are mature osteo-
clasts. (B) shows the measurement of TRAP
activity in treated cultures. Absorbance at405
nm (A405) of lysed cultures plotted against
OPG concentration indicates the conversion
of p-nitrophenyl phosphate into p-nitophenol
in the presence of sodium tartrate.
(C) Mapping the domain of OPG biological
activity using the osteoclast-forming assay.
Various constructs wereused to makemurine
and human OPG proteins of varying lengths.
The construct length (left) and its relative bio-
activity (right) are indicated. Bioactivity is ex-
pressed as the range in protein concentration
(ng/ml) rendering half-maximal activity (ID50).
OPG proteins that are not active are indicated
(N.A.). Note that truncation of the molecule
proximal to cysteine residue 185, when fused
to human Fc, led to a complete lossof biologi-
cal activity.
osteoclast-forming assay (Lacey et al., 1995). This cul- the OPG-expressingmice and controls containedosteo-
clast precursors (Figure 5A), which confirms that thereture system allows maturation of osteoclasts from he-
matopoietic precursors that express multiple differenti- is no intrinsic defect in osteoclast development in OPG
mice. At 100 and 10 ng/ml of the murine OPG, osteoclastation markers of the osteoclast lineage, most notably
TRAP. Recombinant murine OPG fused to the human formation from spleen cells of both control and OPG
mice was completely inhibited (Figure 5A). The levels ofimmunoglobulin IgG1 Fc domain (murine OPG [22±401]-
Fc) was purified from CHO cell-conditioned media and TRAP were also inhibited in the presence of OPG, with
an ID50 of about 1 ng/ml (Figure 5B). The levels of TRAPsubsequently tested in the osteoclast-forming assay. In
the absence of exogenous OPG, spleen cells from both activity in culture lysates appeared to correlate with the
A Novel Secreted Osteoclastogenesis Inhibitor
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Figure 6. Recombinant OPG Administration
Increases Bone Density in Normal Mice
Four-week-old male BDF1 mice (n 5 5 per
group) received subcutaneous injections of
either vehicle (A and B), murine OPG [22±
401]-Fc protein (10 mg/kg/day) (C and D), or
the known antiresorptive pamidronate (5 mg/
kg/day) (E and F) for seven days. The left
panels are photomicrographs of Von Kossa-
stained frozen sections of the proximal tibial
metaphysis. Mineralized bone matrix is
stained black in these micrographs, and
shown is a similar visible increase in bone
density in OPG-treated and pamidronate-
treated mice relative to controls. Bone den-
sity was measured in the region highlighted
(enclosed rectangles) and found to be in-
creased in OPG and pamidronate-treated
mice about 2- to 3-fold (see text). The right
panels are photomicrographs of decalcified
Masson's trichrome-stained sections of the
distal femoral metaphysis of vehicle-treated
(B), OPG-treated (D), or pamidronate-treated
(F) mice. Development of a marbled appear-
ance in the bone owing to cartilage retention
in the OPG-treated (D) and pamidronate-
treated (F) mice is similar to that seen in the
high expressing founder 17 (see Figure 3).
Bars in (A) and (B) indicate intervals of 1 mm
and 100 mm, respectively.
relative number of osteoclasts seen by TRAP cytochem- for this and other bisphosphonates (Sietsema et al.,
1989). Based on histomorphometry of the proximal tibialistry.
Additional forms of the human and murine OPG mole- metaphysis (Figures 6A, 6C, and 6E), the OPG-treated
mice had an approximately 3-fold increase in trabecularcules were tested to determine portions of the protein
required for biological activity (Figure 5C). Truncation of bone compared to controls (31.1% 6 4.1% versus
12.0% 6 2.4%, respectively; mean 6 SD, n 5 5), which isOPG N-terminal to cysteine 185 inactivates this mole-
cule, presumably by disrupting the SS3 disulfide bond highly significant (p , 0.0001). Pamidronate treatments
also significantly increased trabecular bone volumeof the TNFR-like domain 4 (see Figure 1B). However,
loss of the C-terminal portion of the molecule up to aa (22.9% 6 0.6% over controls, p , 0.001). Administration
of recombinant OPG or pamidronate also increased194 did not affect activity. Thus, the N-terminal portion
of OPG containing the TNFR-like domain is necessary bone density in the metaphysis of the distal femur (Fig-
ures 6B, 6D, and 6F) and produced a pattern of cartilageand sufficient to inhibit osteoclastogenesis. All active
forms of OPG inhibit osteoclastogenesis in a dose- retention within the bone trabeculae similar to that seen
in transgenic founder 17 (Figure 3). In the OPG recipi-dependent manner and possess half-maximal activities
in the range observed for other potent cytokines in their ents, the serum level of OPG 24 hr after the last injection
was 320 6 176 ng/ml, a level similar to the steady-respective in vitro assays (Figure 5C).
state levels in transgenic mice with a severe phenotype.
Collectively, these data indicate that OPG acts as anRecombinant OPG Increases Bone Density In Vivo
The transgenic model of OPG expression suggests that antiresorptive agent that negatively regulates osteoclast
maturation and can lead to the excess accumulation ofincreases in bone and cartilage are due to elevated
levels of circulating OPG. To prove this, OPG was admin- newly synthesized bone and cartilage in vivo.
istered to normal mice, and its effects on bone mass
were measured and compared to the known antiresorp- Recombinant OPG Protects Rats against
Ovariectomy-Associated Bone Losstive bisphosphonate, pamidronate (Sietsema et al.,
1989). Young rapidly growing mice (4 weeks of age) A key test of the biological activity of OPG is to demon-
strate that it can protect against pathological decreaseswere subcutaneously injected daily with murine OPG
[22±401]-Fc protein (10 mg/kg/day) or pamidronate (5 of bone volume associated with loss of estrogen in ovari-
ectomized rats. The ovariectomized rat is a commonlymg/kg/day). After 7 days, both the OPG and pamidro-
nate recipients exhibited a marked increase in trabecu- used animal model of human postmenopausal bone loss
that is mediated by increased osteoclast activity (Chris-lar bone in the area of the tibial metaphysis relative to
controls (Figure 6). A similar activity has been reported tiansen et al., 1980; Kalu et al., 1989). Fisher rats, aged
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cell survival, proliferation, and differentiation (Smith et
al., 1994). Soluble forms of these receptors have been
identified and are generated either by cleavage from the
cell membrane or as secreted molecules encoded by
alternatively spliced mRNAs (Kohno et al., 1990; Hughes
and Crispe, 1995). The soluble forms of these receptors
are likely to capture and bind their cognate ligands,
thereby preventing the ligands from activating their cel-
lular targets. Several members of the Pox family of vi-
ruses express soluble TNF receptors, which aid in neu-
tralizing the antiviral effects of TNFa (Smith et al., 1994;
Schreiber et al., 1996). Interestingly, the only form of
OPG that we have isolated is a secreted protein. Based
on our analysis, we have not detected any qualitatively
altered transcripts capable of encoding a transmem-
brane form of the protein.
Systemic delivery of OPG via the expression of rat or
murine opg transgenes in mice results in severe yet
nonlethal osteopetrosis. The osteopetrotic phenotype
caused by OPG overexpression differs significantly from
those observed in other mouse osteopetrotic models,
Figure 7. Recombinant OPG Blocks Ovariectomy-Induced Bone whether generated by the disruption of specific genes
Loss in Fisher Rats (src or fos gene knockouts) or in naturally occurring
Twelve-week-old Fisher rats were ovariectomized and treated for mouse mutants (Marks, 1989; Yoshida et al., 1990). Os-
14 days with vehicle (OVX), murine OPG [22±401]-Fc protein (5 mg/ teopetrosis is often lethal in those models, and bone
kg/day) (OVX OPG), orpamidronate (5mg/kg/day) (OVX PAM). Sham-
formation, as well as tooth eruption, are abnormal. opgoperated animals were treated with vehicle (SHAM). Bone volume
transgenic mice are, in contrast, of normal size, havein the proximal tibial metaphysis was increased in OPG OVX rats
no apparent defects in tooth eruption, and have normallyrelative to OVX (upper panel, asterisk means different to ovariecto-
mized animals, p , 0.05), and a similar trend is apparent in the SHAM shaped bones. Histologically, the opg transgenic mice
and PAM OVX groups. Osteoclast numbers in the distal femoral have a marked reduction in trabecular osteoclasts but
metaphysis were decreased in the OPG OVX and PAM OVX relative no deficiency of osteoclast precursors, suggesting a
to OVX (lower panel, asterisk means different to ovariectomized
defect in the later stages of osteoclast differentiation.animals, p , 0.05).
opg transgenic mice do not appear to have any defects
in the normal development of osteoclast progenitor
12 weeks, were ovariectomized and after 4 days treated cells, since osteoclast-like cells develop readily from
for 2 weeks with recombinant murine OPG [22±401]-Fc in vitro cultures of opg transgenic spleen cells. Taken
protein (5 mg/kg/day) or pamidronate (5 mg/kg/day). together, these findings suggest that OPG, and perhaps
OPG-treated rats exhibited an increase in bone volume its ligand(s) or receptor(s), naturally serve to regulate
and a decrease in osteoclast numbers relative to con- bone density by modulating osteoclast differentiation
trols (Figure 7). The known antiresorptive, i.e., pamidro- from hematopoietic precursors.
nate, had effects similar to OPG and those reported Recombinant OPG protein inhibits osteoclast differ-
for other bisphosphonates (Wronski et al., 1989). These entiation in a dose-dependent manner in an in vitro os-
data show that OPG can act as a protective agent teoclast-forming assay. The N-terminal 185 amino acids
against inappropriately high rates of osteoclast-medi- of OPG are required for activity, and truncations that
ated bone resorption, in addition to its effects in normal disrupt the predicted SS3 bond of domain 4 eliminate
animals. activity. This suggests that the TNFR-related portion of
OPG, which resembles the ligand-binding domain of
Discussion other related receptors, is sufficient for arresting osteo-
clast maturation in vitro. One hypothesis for this activity
OPG is a novel secreted member of the TNFR superfam- is that OPG is neutralizing a TNF-related protein that
ily, which inhibits osteoclast maturation and protects normally acts as an osteoclast maturation factor. There
bone from both normal osteoclast remodeling and ovari- are no known members of the TNF family that appear
ectomy-associated bone loss. This protein contains two to possess this activity, although TNFa can induce bone
characterized domains: the N-terminal half, which har- resorption (Bertolini et al., 1986) and increase osteoclast
bors four tandem cysteine-rich TNFR motifs, and the formation in vitro (Thomson et al., 1987). It is noteworthy
C-terminal half, which is unrelated to any known protein that TNF-binding protein, which does neutralize TNFa
sequences but appears to function in the association activity, fails to inhibit osteoclastogenesis in vitro and
of OPG monomers as they are processed within the does not induce the accumulation of bone and cartilage
secretory pathway (W. J. B. and A. C., unpublished data). in normal mice (D. L. L. and H.-L. T., unpublished data).
The TNFR superfamily consists primarily of transmem- Alternatively, OPG may bind to a TNF-related protein
brane proteins that elicit signal transduction in a variety that acts as a receptor, a plausible theory since a major-
of cells and are known to mediate diverse biological ity of TNF family members are transmembrane proteins.
Several lines of evidence indicate that OPG may beresponses, including cytotoxicity and apoptosis, and
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and was used in fluorescence in situ hybridization (FISH) analysis toa key determinant regulating bone metabolism. First,
determine itschromosomal localization in metaphasechromosomesoverexpression in transgenic mice at a site distant to
as described (Heng et al., 1992).the bone results in a dramatic increase in bone density
and inhibition of osteoclast maturation. The severity of Expression and Analysis of Recombinant OPG Protein
the phenotype in the transgenics correlates with the Mouse and human OPG-Fc fusion protein vectors were constructed
levels of RNA expression in the liver and with circulating by PCR as previously described (Byrn et al., 1990) with minor modifi-
cations. The full-length opg reading frame was PCR amplified, thenlevels of protein. Second, OPG specifically inhibits os-
linked to glutamic acid residue 211 of the human IgG1 Fc regionteoclastogenesis in vitro. Third, systemic administration
through an artificial NotI adapter, creating the following junctionof OPG produces an increase in bone density in the
sequence: KISCLAAAEPKSCD.
tibial metaphysis and blocks the loss of bone induced Variants of the human and mouse full-length OPG-Fc fusion pro-
by ovariectomy. Fourth, in situ hybridization data indi- teins were constructed by PCR amplifying the OPG regions encod-
cate that the mouse gene is expressed at high levels ing residues 1±201 (human), 1±194 (mouse), 1±185 (mouse), and
1±180 (mouse), then fused to Fc as described above. The OPG-Fcin the cartilaginous primordia of bones throughout the
chimeric sequences were then cloned into the plasmid vectorfetus. Lastly, the human gene is localized to chromo-
pCEP4 (Invitrogen, San Diego, CA). The parent pCEP4 and pCEP4some 8 q23±24, a region closely linked to the gene in-
OPG-Fc vectors were lipofected into 293-EBNA-1 cells (Invitrogen,
volved in hereditary multiple exocytoses (HME), a skele- San Diego, CA) and selected in 100 mg/ml hygromycin using the
tal disorder resulting in bone malformation and, in some manufacturer's recommended methods. Serum-free media was pro-
instances, chondrosarcoma (Ahn et al., 1995). This same duced, and the OPG-Fc fusion proteins were purified by protein
A/G-affinity chromatography (Ey et al., 1978). The mouse and humanlocus harbors the gene for the bone morphogen
opg cDNAs were also cloned into the eukaryotic expression vectorBMP-1 (Tabas et al., 1991), a member of the TGFb super-
pDSRa and expressed in stably transformed CHO cell lines as pre-family that has potent bone-forming activity in vivo, even
viously described (DeClerk et al., 1991). The purification of native
in soft tissue sites away from bone. This raises thepossi- recombinant OPG from CHO cell-conditioned media will be de-
bility that this region of chromosome 8 may harbor a scribed in another publication (M. K. and E. D., unpublished data).
gene cluster involved in the regulation of bone develop- Rabbit polyclonal antibodies were raised to purified murine OPG
[22±401]-Fc fusion protein by subcutaneous injection of antigenment and metabolism.
emulsified in adjuvant, then affinity purified. A CHO cell line overex-In summary, a novel member of the TNF receptor
pressing the murine OPG protein was metabolically labeled andfamily has been identified, and its biological function
immunoprecipitated as previously described (Boyle et al., 1991). In
deduced. Unlike othermembers of this family, Osteopro- brief, subconfluent cultures were pulse-labeled with approximately
tegerin appears to function as a secreted protein. In 1.0 mCi/ml of [35S]-Translabel (ICN, Irvine, CA) for 30 min, then
addition, a novel gain-of-function model for nonlethal chased with complete media for the indicated time interval. The
conditioned media was removed and made 1% in NP-40 (v/v), andosteopetrosis hasbeen generated by transgenic overex-
the cell monolayers were lysed with RIPA buffer. Both the mediapression of OPG in mice. The phenotype of this model
and cell lysates were clarified, then immunoprecipitated. Westerndiffers significantly from models generated by the tar-
blots of conditioned media and mouse serum samples were per-
geted mutagenesis of the src and fos genes, and from formed as previously described (Kamps and Sefton, 1988). The blots
naturally occurring mutant mouse strains, such as the were probed with anti-OPG antibodies (0.1 mg/ml), and immune
Op mouse (CSF-1 disruption). Our analysis suggests complexes detected by enhanced chemiluminescence (Amersham)
after exposure to Kodak X-ray film.that a step in osteoclast differentiation is impacted by
OPG in vitro. Therefore, we propose that OPG is a se-
mRNA Analysiscreted regulator of bone density that can act locally and
Northern blots of either total or poly(A)1 mRNA were prepared assystemically by negatively regulating osteoclast matura-
described (JaÈ hner and Hunter, 1991) or purchased from a commer-
tion. Our initial findings imply a utility for OPG in the cial source (MTN's, Clonetech, Palo Alto, CA). All blots were probed
treatment of osteopenic disorders that arecharacterized under stringent conditions with a 32P-dCTP-labeled rat, mouse, or
by excessive osteoclast activity, such as primary osteo- human opg DNA probe as indicated. These blots were subsequently
probed with the mouse gapdh cDNA to verify the integrity of theporosis, Paget's disease of the bone, hypercalcemia of
blotted mRNA. Northern blot analysis was also performed onmalignancy, and osteolytic metastases.
founder liver tissue RNA to assess the expression of the rat opg
transgene.
In situ hybridization was performed on mouse embryos fixed inExperimental Procedures
4% paraformaldehyde. Antisense and sense RNA probes to murine
OPG (bp 803±1000) were transcribed using viral RNA polymerasesComputational Biology
in the presence of [35S]UTP from a PCR-generated template con-A cDNA library was constructed using mRNA isolated from rat em-
taining the T7 promoter. Embryo sections were hybridized with thebryonic d20 intestine for EST analysis (Adams et al., 1991). The
appropriate probe, then covered with emulsion and exposed 2±3resulting 59 nucleotide sequence obtained from individual clones
weeks at 158C. The slides were counter stained with methyl greenwas translated and compared with the existing database of known
prior to photography.protein sequences using a modified version of the FASTA program
(Pearson, 1990). Analyses for the presence of specific protein motifs
were carried out using a modified sequence profile (LuÈ thy et al., Generation of opg Transgenic Mice
The coding region for either the rat or murine opg cDNA was sub-1994).
A full-length opg cDNA clone containing a 2.4 kb insert (pB1.1) cloned free of mutations into an expression vector placing it under
the control of the human ApoE promoter and liver-specific enhancerwas isolated from a fetal rat intestine cDNA library by colony hybrid-
ization and sequenced. The mouse and human homologs of the rat element (Simonet et al., 1994). For microinjection, the ApoE-OPG
plasmid was purified, and the transgene insert isolated. Single-cellopg cDNA were isolated from either mouse or human normal kidney
cDNA libraries (Clontech, Palo Alto, CA) by PCR amplification and embryos from BDF1 mice were injected essentially as described
(Brinster et al., 1985) and cultured overnight in a CO2 incubator.colony hybridization, then sequenced. A human DNA clone was
obtained from a genomic P1 library (Genome Systems Inc., St. Louis, Fifteen to twenty 2-cell embryos were transferred to the oviducts
of pseudopregnant CD1 female mice. Transgenic offspring wereMO) by plaque hybridization with a labeled human opg cDNA probe
Cell
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identified by screening for the ApoE-opg transgene in DNA prepared injection, rats were euthanized, and the right tibia and femur re-
moved. Bone density was determined in frozen sections of the distalfrom ear biopsies as described (Simonet et al., 1994).
tibial metaphysis as described above. The femur was decalcified in
formic acid, dehydrated, mounted, and stained with hematoxylinNecroscopy and Pathological Analysis
and eosin. Osteoclast numbers were determined in a region 1 3 0.6At 8±10 weeks of age, 5 transgenic founder and 5 control animals
mm proximal to the growth plate in the distal femoral metaphysis.were necropsied. Radiography was performed prior to the gross
Osteoclasts were identified microscopically based upon morphol-dissection. Bone tissue was decalcified using a formic acid solution,
ogy and enumerated relative to bone perimeter with the aid of aand all sections were stained with H and E. In addition, staining with
digitizing platen and camera lucida. Measurements were analysedGomori's reticulin andMasson's trichrome was performedon certain
using Osteomeasure software (Osteometrics, Atlanta, GA). Statisti-tissues. To assess the status of matrix mineralization, frozen sec-
cal significance of results was evaluated by Dunnett's test to correcttions of nondecalcified bone were stained using the Von Kossa
for multiple comparisons (JMP Statistical Software, SAS Institute,method. Using this method, the mineralized matrix is black, while
Cary, NC).other tissues stain red. Enzyme histochemistry was performed to
determine the expression of TRAP. Immunohistochemistry for the
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on formalin-fixed paraffin-embedded 4 mm sections using the rat
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